Validating Multiple Myeloma Cell Lines
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Corresponding Organization :
Other organizations : Maine Medical Center Research Institute, Tufts University, University of Maine, Mayo Clinic, Novo Nordisk Foundation, University of Copenhagen, Vejle Sygehus, Garvan Institute of Medical Research, Norwich University Applied Research Institute, University of Southern Denmark, Odense University Hospital, Lillebaelt Hospital
Variable analysis
- RNA-Seq data used to validate the MM.1S, OPM-2, and RPMI-8226 cells
- Variants compared to RNA-Seq variants present in the Cancer Cell Line Encyclopedia
- Known translocations confirmed using gene fusion predictions from the MAPRSeq pipeline and compared against CCLE gene fusion predictions
- 3T3-L1 cells from ATCC
- 5TGM1 cells have not been validated at this time
- None specified
- None specified
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!